Company: FCRS
Filing Date: 2025-09-17
Form Type: S-1/A
Source: 0001213900-25-088487
Chunk: 149

Company: FutureCrest Acquisition Corp.
Filing Date: 2025-09-17
Form: S-1/A
Chunk 149
---
ation of our initial business combination. The assumed exercise of the warrants would cause the actual dilution to the public shareholders to be higher, particularly where a cashless exercise is utilized. Further, the issuance of additional ordinary or preference shares in connection with the closing of our initial business combination may significantly dilute the equity interest of public shareholders, which dilution would even further increase if the anti -dilutionprovisions in the Class B ordinary shares resulted in the issuance of Class A ordinary shares on a greater than one -for-onebasis upon conversion of the Class B ordinary shares. Further, the Class A ordinary shares issuable in connection with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti -dilutionrights of our founder shares that may result in an issuance of Class A ordinary shares on a greater than one -for-onebasis upon conversion. If we raise additional funds through equity or convertible debt issuances in connection with a business combination, our public shareholders may also suffer significant dilution. This dilution would increase to the extent that the anti -dilutionprovision of the founder shares results in the issuance of Class A shares on a greater than one -to-onebasis upon conversion of the founder shares at the time of our initial business combination. In addition, the conversion of any working capital loans would further increase the dilution to our public shareholders. As a result of the compensation to be paid to the sponsor, Class A ordinary shares issuable in connection with the conversion of the founder shares, and securities to be issued to the sponsor in the private placement, including the exchange of the private placement warrants, and conversion of any working capital loans, our public shareholders may experience substantial dilution. The following table illustrates the difference between the public offering price per unit and our NTBV per share, as adjusted to give effect to this offering and assuming redemption of our public shares at varying levels and the full exercise and no exercise of the over -allotmentoption:

| As of June 30, 2025 |                                                 |     |                |      |     |            |      |     |                |      |     |            |      |     |                |      |     |            |      |     |            |   |     |            |       |
|:--------------------|------------------------------------------------:|:----|:---------------|-----:|:----|:-----------|-----:|:----|:---------------|-----:|:----|:-----------|-----:|:----|